SEC Filing Summary: Manhattan Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Manhattan Pharmaceuticals, Inc. on November 14, 2003, reporting events occurring as of November 5, 2003. The filing discloses the completion of a private placement of equity securities. Note: The request metadata references "TG THERAPEUTICS, INC.", but the filing text explicitly identifies the registrant as Manhattan Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of 1,000,000 shares of Series A Convertible Preferred Stock.
- Gross Proceeds: $10,000,000 (at $10.00 per share).
- Transaction Costs: $700,000 in commissions and $150,000 in non-accountable expenses paid to selling agents.
- Net Proceeds: Approximately $9,150,000 (calculated as gross proceeds less stated costs).
- Dividend Terms: 5% per annum, payable in semi-annual installments in additional shares of Preferred Stock.
- Conversion Terms: Convertible into common stock at $1.10 per share (approximately 9.1 common shares per preferred share).
- Warrants Issued: 5-year warrants to selling agents for 909,091 shares of common stock at an exercise price of $1.10 per share.
Other Metrics: The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or liquidity ratios outside of this specific transaction.
Material Changes Versus Prior Period
This filing represents a discrete capital event rather than a periodic financial update. Consequently, no comparative revenue, profit, or balance sheet changes versus a prior comparable period are disclosed in this document.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release dated November 10, 2003, but does not contain specific forward-looking guidance, management commentary on future operations, or a detailed risk factor analysis within the text provided. The transaction was executed under Section 4(2) of the Securities Act of 1933 and Regulation D.
Key Facts for Investor Verification
- Verify the exact net cash proceeds after all offering expenses are finalized.
- Confirm the dilution impact on existing common shareholders upon conversion of the 1,000,000 preferred shares (approx. 9.1 million common shares) and exercise of the 909,091 warrants.
- Review the attached press release (Exhibit 99.1) for the intended use of proceeds and strategic rationale.
- Check subsequent filings for the actual payment of the 5% dividend in kind and any early conversions.